MacroGenics Inc.
MacroGenics Inc. is listed today as MacroGenics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2011 | $12 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company MacroGenics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaborative and other agreements $87.18 million (58%), Contract manufacturing $52.63 million (35%), Royalty revenue $9.69 million (6%).
Annual report (SEC XBRL) · Dec 2025
MacroGenics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2011).
SEC Form D · Jan 2011
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2011
Products and services#
No products or services of MacroGenics Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Biopharma Partners III Gmbh & Co Beteiligungs KG | Fund or asset manager | not stated | not stated | Held Series B, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Alta Biopharma Partners III LP | Fund or asset manager | not stated | not stated | Held Series B, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Alta Embarcadero Biopharma Partners III LLC | Fund or asset manager | not stated | not stated | Held Series B, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Interwest Investors Q VIII LP | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Interwest Investors VIII L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| InterWest Management Partners VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Interwest Partners VIII LP | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| TPG Group Holdings (SBS) Advisors, Inc. | Fund or asset manager | not stated | not stated | Held Series B-1, C and D-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 3 investors.
Largest shareholders today
Institutions holding MacroGenics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$24 M9.62%
- Armistice Capital, LLC$23 M9.39%
- Vanguard Capital Management LLC$10 M4.19%
- Acadian Asset Management LLC$10 M3.98%
- Two Sigma Investments, LP$9 M3.73%
- Renaissance Technologies LLC$8 M3.41%
- Mackenzie Financial Corp$8 M3.15%
- Vanguard Portfolio Management LLC$8 M3.12%
- Ra Capital Management, L.P.$7 M2.92%
- Geode Capital Management, LLC$7 M2.74%
- Marshall Wace, LLP$5 M2.10%
- Wasatch Advisors LP$5 M1.97%
- ADAR1 Capital Management, LLC$5 M1.93%
- Millennium Management LLC$5 M1.87%
- State Street Corp$5 M1.83%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| James Karrels | Executive officer | Jan 2011 |
| Scott Koenig | Executive officer | Jan 2011 |
| Arnold Oronsky | Director | Jan 2011 |
| Ed Hurwitz | Director | Jan 2011 |
| Ken Galbraith | Director | Jan 2011 |
| Michael Steinmetz | Director | Jan 2011 |
| Paul Sekhri | Director | Jan 2011 |
| Paulo Costa | Director | Jan 2011 |
| Scott Koenig | Director | Jan 2011 |
Went public since 2013. Its SEC number is that of a company listed on a stock exchange.